Lucy Foley appointed Vice Chair of BIA Manufacturing Advisory Committee
The BioIndustry Association (BIA) is pleased to announce the appointment of Lucy Foley, Chief Technology Officer at eXmoor Pharma, as Vice Chair of its Manufacturing Advisory Committee (MAC).
The MAC brings together leading experts from across the UK’s biologics and cell and gene therapy manufacturing sector. It plays a critical role in supporting the BIA’s policy work, driving innovation, and promoting best practice to reinforce the UK’s position as a global leader in life sciences manufacturing.
Lucy brings more than 15 years of experience in biomanufacturing, spanning bioprocessing, facility design, and the industrialisation of advanced therapies. She previously led the CPI Biologics and RNA Centre of Excellence as part of the UK’s Vaccines Taskforce response.
Commenting on her appointment, Lucy said:
The BIA MAC plays an essential role in shaping the future of UK life sciences manufacturing. From very early on in my career, the BIA and BIA MAC members have demonstrated great leadership for our industry, championing the need for manufacturing capability and growth within the UK. They have always been accessible and helpful from both a company and individual perspective. I’m looking forward to working with industry colleagues to share expertise, tackle sector challenges, and help drive innovation and growth across the biomanufacturing ecosystem.
Lucy succeeds Sharon Grimster, who retired earlier this year following decades of service to the BIA MAC, including as both Chair and Vice Chair.
Netty England MBE, Bioprocessing Consultant at BIA and MAC Secretariat, said:
After decades of dedicated service to the BIA MAC, Sharon Grimster is stepping down. A huge personal thank you to Sharon for her leadership, warmth, creativity and friendship — she has been an absolute joy to work with. Sharon leaves very big shoes to fill, and I’m delighted that Lucy Foley is stepping into this important role. I’m very much looking forward to working with her as we continue to strengthen UK biomanufacturing.
